Ofatumumab in the treatment of chronic lymphocytic leukemia

Drugs of Today

Volumn 46, Issue 7, 2010, Pages 451-461

  Tsimberidou, Apostolia Maria ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BENDAMUSTINE; CD20 ANTIGEN; CETIRIZINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GLUCOCORTICOID; LENALIDOMIDE; OFATUMUMAB; PARACETAMOL; PENTOSTATIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ANEMIA; ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BLOOD TOXICITY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG BINDING; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; PNEUMONIA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SWEATING; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; EVIDENCE-BASED MEDICINE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; TREATMENT OUTCOME; VIDARABINE;

EID: 77958193889     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.71497416     Document Type: Review

References (47)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J. Cancer Statistics, 2008. CA Cancer J Clin 2008, 58(2): 71-96.
2. Keating, M.J., O'Brien, S., Albitar, M. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23(18): 4079-88. (Pubitemid 46211313)
3. Robak, T. Recent progress in the management of chronic lymphocytic leukemia. Canc Treat Rev 2007, 33(8): 710-28. (Pubitemid 350089291)
4. Zhang, B. Ofatumumab. MABs 2009, 1(4): 326-31.
5. Keating, M.J., O'Brien, S., Kontoyiannis, D. et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002, 43(9): 1755-62. (Pubitemid 34874007)
6. Traynor, K. Ofatumumab approved for advanced CLL. Am J Health Syst Pharm 2009, 66(23): 2062.
7. Coiffier, B., Lepretre, S., Pedersen, L.M. et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 2008, 111(3): 1094-100. (Pubitemid 351213387)
8. Osterborg, A., Kipps, T., Mayer, J. et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial. Blood 2008, 112(11): Abst 328 [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008).
9. Nadler, L.M., Korsmeyer, S.J., Anderson, K.C. et al. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest 1984, 74(2): 332-40.
10. Stashenko, P., Nadler, L.M., Hardy, R., Schlossman, S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125(4): 1678-85.
11. Stashenko, P., Nadler, L.M., Hardy, R., Schlossman, S.F. Expression of cell surface markers after human B lymphocyte activation. PNAS U S A 1981, 78(6): 3848-52. (Pubitemid 11060476)
12. van Meerten, T., Hagenbeek, A. CD20-targeted therapy: The next generation of antibodies. Semin Hematol 2010, 47(2): 199-210.
13. Huh, Y.O., Keating, M.J., Saffer, H.L., Jilani, I., Lerner, S., Albitar, M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001, 116(3): 437-43. (Pubitemid 32851978)
14. Tsimberidou, A.M., Catovsky, D., Schlette, E. et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006, 107(1): 125-35. (Pubitemid 43941641)
15. Demko, S., Summers, J., Keegan, P., Pazdur, R. FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008, 13(2):167-174. (Pubitemid 351342581)
16. O'Brien, S.M., Kantarjian, H., Thomas, D.A. et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19(8): 2165-70. (Pubitemid 32366970)
17. Hallek, M., Fingerle-Rowson, G., Fink, A. et al. First-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia: Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. Blood 2009, 114(22): Abst 535 [51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009].
18. Teeling, J.L., French, R.R., Cragg, M.S. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104(6): 1793-1800.
19. Robak, T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther 2008, 10(3): 294-309.
20. Fishwitd, D.M., O'Donnell, S.L., Bengoechea, T. et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechol 1996, 14(7): 845-51. (Pubitemid 26239182)
21. WO-2004035607: Human monoclonal antibodies against CD20. Medarex Inc; Genmab A/S WORLD PATENT 2004 April 29.
22. Hagenbeek, A., Gadeberg, O., Johnson, P. et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008, 111(12): 5486-95.
23. ARZERRA (ofatumumab) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
24. Dechant, M., Teeling, J., Beyer, T. et al. Novel fully human CD20 antibodies with different mechanisms of action. Blood 2003, 102(11, Part 1): Abst 349.
25. Mackus, W.J.M., Teeling, J., Brakel, J. et al. In vivo characterization of HuMax-CD20, a novel fully human antibody targeting CD20. Immunobiology (1979) 2004, 209(4-6): Abst G.10 [Jt Annu Meet German Dutch Soc Immunol (October 20-23, Maastricht) 2004].
26. Teeling, J.L., Mackus, W.J., Wiegman, L.J. et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177(1): 362-71.
27. Mous, R., Savage, P., Eldering, E., Teeling, P., van Oers, M.H., van Lier, R.A. Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. Leuk Lymphoma 2008, 49(8): 1592-602.
28. Bleeker, W.K., Munk, M.E., Mackus, W.J. et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Brit J Haemat 2008, 140(3): 303-12.
29. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S., Rai, K.R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996, 87(12): 4990-7. (Pubitemid 26189840)
30. Genmab's HuMax-CD20 depletes leukemia cells in phase I/II trial. Genmab A/S PRESS RELEASE 2005 Sept 15.
31. Coiffier, B., Tilly, H., Pedersen, L. et al. HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia. Early results from an ongoing phase I/II clinical trial. Blood 2005, 106(11): Abst 448 [47th Annu Meet Am Soc Hematol (December 10-13, Atlanta) 2005].
32. Coiffier, B., Tilly, H., Pedersen, L. et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood 2006, 108(11): Abst 2842 [48th Annu Meet Am Soc Hematol (December 9-12, Orlando) 2006].
33. Wierda, W.G., Kipps, T.J., Mayer, J. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarablne-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10): 1749-55.
34. Wierda, W.G., Kipps, T.J., Durig, J. et al. Ofatumumab combined with fludarabine and cyclophosphamide shows high activity in patients with previously untreated chronic lymphocytic leukemia: Results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood 2009, 114: Abst 207 [51st Annu Meet Am Soc Hematol (Nov New Orteans).
35. Genmab begins phase II combination trial of HuMax-CD20 for CLL. Genmab A/S Press Release 2006 Dec 11.
36. NCT00410163: Ofatumumab with fludarabine and cyclophosphamide in B-CLL patients. Genmab A/S CLINICALTRIALS.GOV 2008 Jan 16.
37. NCT00824265: Ofatumumab added to fludarabine-cyclophosphamide vs. fludarabine-cyclophosphamide combination in relapsed subjects with chronic lymphocytic leukemia. http://www.clinicaltrials.gov/ct2/show/NCT00824265?term= ofatumumab+fc&rank=1.
38. NCT01039376: Ofatumumab maintenance treatment vs. no further treatment in relapsed CLL responding to induction therapy. GlaxoSmithKline. http://clinicaltrials.gov/ct2/show/Na010393767term=Na01039376&rank=1.
39. NCT01024010: Phase II trial of pentostatin, cyclophosphamide, and ofatumumab for previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT01024010?term= ofatumumab+cll&rank=1.
40. NCT01002755: Combination of lenalidomlde and ofatumumab in patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. http://www.clinicaltrials.gov/ct2/show/NCTO1002755?term=ofatumumab+cll&rank= 3.
41. NCT00802737: A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance in CLL patients who progressed following response or stable disease after ofatumumab treatment in Hx-CD20-406. http://www.clinicaltrials.gov/ct2/show/ NCT00802737?term=ofatumumab+cll&rank=5.
42. NCT01077622: A phase I/II, a single arm, open-label study of ofatumumab (GSK1841157) in patients with previously treated chronic lymphocytic leukemia. http://www.clinicaltrials.gov/ct2/show/NCT01077622?term=ofatumumab+cll&rank= 8.
43. NCT00748189: A phase III, open label, randomized, multicenter trial of ofatumumab added to chlorambucil versus chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia. http://www.clinicaltrials. gov/ct2/show/NCT00748189?term=ofatumumab+cll&rank=10.
44. NCT01010568: Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia/ small lymphocytic leukemia/ http://www.clinicaltrials.gov/ ct2/show/NCT01010568?term=ofatumumab+cll&rank=2.
45. Bingham, C.O. 3rd. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008, 66(3): 210-5.
46. Ostergaard, M., Baslund, B., Rigby, W. et al. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: Early results from an ongoing, double-blind, randomized, placebo controlled clinical trial. Arthritis Rheum 2007, 56(9, Suppl.): Abst 2086 [71st Annu Sci Meet Am Coll Rheumatol (November 6-11, Boston) 2007].
47. Castillo, J., Milani, C., Mendez-Allwood, D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 2009, 18(4): 491-500.